News

Public · Published

Sangamo Therapeutics Reports August Cash of $23.2 Million in Chapter 11 Updates

Sangamo Therapeutics reported August cash of $23.2 million, assets of $147.9 million and liabilities of $107.3 million in its Chapter 11 updates. The month recorded a $14.4 million loss, with cumulative losses of $29.4 million since filing.

Published:

Updated:

What happened

Sangamo Therapeutics reported August cash of $23.2 million, assets of $147.9 million and liabilities of $107.3 million in its Chapter 11 updates. The month recorded a $14.4 million loss, with cumulative losses of $29.4 million since filing.

Confirmed

Global impact / market context

The company holds less cash than its reported liabilities, which means money available may not cover what it owes. That gap can limit spending on research and operations, pressure talks with lenders and suppliers, and leave little value for shareholders.

Analyst inference

Sangamo's common stock was delisted from Nasdaq and now trades on the OTC Expert Market only through unsolicited quotes, which means buyers and sellers are not actively matched. That limits trading ease and can widen price swings for investors holding the shares.

Analyst inference

What to watch

  1. The company said its unaudited, non-GAAP reports are limited and should not indicate future results, so readers should treat the August figures as preliminary rather than a settled financial picture. Confirmed
  2. Watch whether Sangamo files later monthly operating reports showing cash staying above the $23.2 million August level or whether legal and restructuring costs push the balance lower. Proposed
  3. Track equipment sales like the $2.3 million in August, because continuing asset sales raise cash but can shrink the business and reduce future revenue potential. Analyst inference

Evidence

  • Original source link unavailable